bortezomib文摘国外ratewas
摘要：PURPOSE： To evaluate the toxicity and response rate of bortezomib with concurrent radiotherapy and temozolomide in the treatment of patients with central nervous system malignancies. PATIENTS AND METHODS： This open-label, dose-escalation, Phase Ⅰ clinical study evaluated the safety of three dose levels of intravenously administered bortezomib （0.7, 1.0, and 1.3 mg/m （2）/dose） on Days 1, 4, 8, and 11 of a 21-day cycle, in addition to concurrent radiotherapy and temozolomide at a daily dose of 75 mg/m （2） starting on Day 1. The primary endpoint was dose-limiting toxicity, defined as any Grade 4-5 toxicity or Grade 3 toxicity directly at- tr/butable to protocol treatment, requiring hospitalization and/or radiotherapy interruption.
注：因版权方要求，不能公开全文，如需全文，请咨询杂志社
